Let’s get this straight: if the question is “which one causes more weight loss,” retatrutide wins on every number anyone has published. It isn’t close. A GLP-1-only pill isn’t going to match a triple agonist.
But that’s not the question most people searching “foundayo vs retatrutide” are actually asking. They’re asking whether the extra 10-plus points of weight loss are worth an unapproved drug from an unverified vial — with no label, no pharmacist, and a manufacturer actively suing the seller.
That’s a personal call, and the honest answer is that the two choices carry different kinds of risk, not just different sizes of result.
Foundayo’s strengths: boring and real
A published Phase 3 program in more than 7,000 people
A completed cardiovascular-safety trial
No liver signal in a drug class where liver signals have killed rivals
A defined dose
A price that starts at $149
Foundayo’s weaknesses are just as clear
Smaller results than the injectables
A GI side-effect rate that pushes about one in ten off the top dose
Regain data suggesting it holds a semaglutide-sized loss better than a tirzepatide-sized one
Retatrutide’s future
It may well become the strongest drug in the class. In early 2027 Lilly will file, and eventually there’ll be a label. Until then, the trial data describes the molecule. It doesn’t describe what’s in a gray-market vial.
Conclusion
Foundayo is a moderate drug you can get legally. Retatrutide is a remarkable drug you can’t. Most of the decision is in that sentence.